Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8221 to 8235 of 8905 results

  1. Implantable cardioverter defibrillators for arrhythmias (TA95)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  2. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1064

    Withdrawn guidance

  3. Computerised cognitive behaviour therapy for depression and anxiety (TA97)

    The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.

    Withdrawn guidance

  4. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)

    This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.

    Withdrawn guidance

  5. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1128.

    Withdrawn guidance

  6. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guidance

  7. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Withdrawn guidance

  8. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Withdrawn guidance

  9. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Withdrawn guidance

  10. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Withdrawn guidance

  11. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

    This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.

    Withdrawn guidance

  12. Immunosuppressive therapy for renal transplantation in children and adolescents (TA99)

    This guidance has been updated and replaced by NICE technology appraisal guidance 482.

    Withdrawn guidance

  13. Diabetes (type 2) - rosiglitazone (TA9)

    This guidance has been replaced by NICE technology appraisal guidance 63.

    Withdrawn guidance

  14. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Withdrawn guidance

  15. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Withdrawn guidance